Septerna Announces Novel GPCR-targeted Program Acquired by Vertex
SOUTH SAN FRANCISCO - Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors , today announced that it has signed a...
Source: marketscreener.com